HANSOH PHARMA (03692): Amelec (Ametisulphate Amelecine Tablets) obtained the fifth indication of the National Medical Products Administration's drug registration certificate.
Hansson Pharmaceuticals (03692) announced that the Group's innovative drug Iressa (gefitinib) has been granted a drug registration certificate by the China National Medical Products Administration (NMPA), approving the addition of the indication for "Iressa in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations". This is the fifth indication approved for Iressa.
Hansoh Pharma (03692) announced that its innovative drug Amelec (Ameitinib mesylate tablets) has been granted a drug registration certificate by the National Medical Products Administration of China (NMPA). It has been approved for the indication of "Amelec in combination with Pembrolizumab and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have exon 19 deletion or exon 21 (L858R) substitution mutations in the epidermal growth factor receptor (EGFR)." This is the fifth indication for which Amelec has been approved.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
